A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC
Open accessThe DOI matches its Crossref record.
Abstract
lung cancer, the tumor microbiome has been shown to be less diverse than normal tissue, but the effect of microbial composition alterations in airways prior to diagnosis of lung cancer is unknown. We sought to characterize the microbiome in airways of patients found to have lung cancer on follow-up. Following consent, bronchial brushes were obtained from 48 patients at a high risk of lung cancer. With a mean follow-up of 9.4+-1.2 years, 5/48 were diagnosed with lung cancer, and 3/48 were diagnosed with lung cancer at bronchoscopy. 16S sequencing was performed on bronchial epithelial taken from the airways of each patient, and the QIIME2 platform was used to classify the bacterial populations. The bacterial taxonomy, alpha, and beta diversity measures were compared according to cancer status, and bacterial metagenome functionality was assessed using PICRUSt2. We found that patients with lung cancer and those who would develop it had lower airway bacterial diversity. Further, individuals who developed lung cancer over time displayed significantly different airway microbiome profiles from those who did not, but similar profiles to those who already had cancer (p<0.0001), with global taxonomic shifts observable at the phylum level. Using gene content inference, we observed that the lung-resident bacterial communities of patients with prevalent and incident cancers had significantly different metabolic profiles when compared to patients with no cancer. In particular, we observed an enrichment in the metabolites associated with cancer pathway (Wnt and Notch) activation (p-adjusted<0.0001), implicating a role of lungresident bacterial communities in cancer initiation. Validation in an independent cohort consisting of 55 incident cancer, 18 prevalent cancer, and 263 noncancer subjects is ongoing. Here, we profile the microbial community resident to the lung epithelium, and detect changes in this community years prior to the clinical detection of lung cancer. This work lays a foundation for further prospective studies leveraging microbiome profiles to further our understanding of the role of the lung microbiome in the pathogenesis of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Metadata
- Authors
- Nichols, R., Schulze, C., Bermingham, A., Choy, T., Cregg, J., Kiss, G., Marquez, A., Reyes, D., Saldajeno-Concar, M., Weller, C., Whalen, D., Yang, Y., Wang, Z., Koltun, E. S., Singh, M., Wildes, D., Gill, A. L., Hansen, R., Kelsey, S., Goldsmith, M., & Smith, J.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 15
- Issue
- 2
- Pages
- S13-S14
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3001183380
- Cited by
- 23
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC. https://app.cochat.ai/papers/10.1016/j.jtho.2019.12.035
- The paper
- Nichols, R., Schulze, C., Bermingham, A., Choy, T., Cregg, J., Kiss, G., Marquez, A., Reyes, D., Saldajeno-Concar, M., Weller, C., Whalen, D., Yang, Y., Wang, Z., Koltun, E. S., Singh, M., Wildes, D., Gill, A. L., Hansen, R., Kelsey, S., . . . Smith, J. (2020). A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.12.035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.